All contributors
Onconephrology contributor
Merlini, Giampaolo
Primarily MGRS & paraprotein kidney disease#14 of 46 recognizedHonor roll
44
Clinical papers
8,767
Citations (iCite)
2 / 12
First / senior author
2003–2026
Active years
Output over time
Clinical corpus papers per year — peak 5 in 2018, 2022.
- 2003: 1 paper
- 2004: 1 paper
- 2005: 1 paper
- 2007: 1 paper
- 2012: 1 paper
- 2013: 3 papers
- 2014: 3 papers
- 2015: 2 papers
- 2016: 3 papers
- 2017: 4 papers
- 2018: 5 papers
- 2019: 2 papers
- 2020: 4 papers
- 2021: 2 papers
- 2022: 5 papers
- 2023: 2 papers
- 2024: 2 papers
- 2026: 2 papers
20032026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
MGRS & paraprotein kidney disease38
Myeloma cast nephropathy18
Anticancer drug nephrotoxicity1
Cellular therapy renal effects1
Frequent co-authors
Other recognized contributors who most often share corpus papers with Merlini (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Merlini among the leading contributors (clinical-paper count on that agent).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.